Incidental findings on follow-up fluorodeoxyglucose positron emission tomography studies in lymphoma patients: beware the outlier

References

• Ishimori T, Patel P V, Wahl R L. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005; 46: 752–757
   PubMed Web of Science ®Google Scholar
• Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, Fischer D. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med 2005; 46: 758–762
   PubMed Web of Science ®Google Scholar
• Sonet A, Graux C, Nollevaux M C, Krug B, Bosly A, Vander Borght T. Unsuspected FDG-PET findings in the follow-up of patients with lymphoma. Ann Hematol 2007; 86: 9–15
   PubMed Web of Science ®Google Scholar
• Wang G, Lau E W, Shakher R, Rischin D, Ware R E, Hong E, et al. How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT. Cancer 2007; 109: 117–124
   PubMed Web of Science ®Google Scholar
• Kalkanis D, Stefanovic A, Paes F, Escalon M, Serafini A. Lossos IS. [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leuk Lymphoma 2009; 50: 904–911
   PubMed Web of Science ®Google Scholar
• Kazama T, Swanston N, Podoloff D A, Macapinlac H A. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 2005; 32: 1406–1411
   PubMed Web of Science ®Google Scholar
• Blodgett T M, Ames J T, Torok F S, McCook B M, Meltzer C C. Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin. Clin Nucl Med 2004; 29: 161–163
   PubMed Web of Science ®Google Scholar
• Brink I, Reinhardt M J, Hoegerle S, Altehoefer C, Moser E, Nitzsche E U. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 2001; 42: 591–595
   PubMed Web of Science ®Google Scholar
• Pitini V, Navarra G, Cavallari V, Arrigo C. An accessory spleen wrongly recognised as relapse by positron emission tomography. Eur J Haematol 2006; 77: 270–271
   PubMed Web of Science ®Google Scholar
• Fruchart C, Reman O, Le Stang N, Musafiri D, Cheze S, Macro M, et al. Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study. Leuk Lymphoma 2006; 47: 2547–2557
   PubMed Web of Science ®Google Scholar
• Ng A P, Wirth A, Seymour J F, Lee M, Hogg A, Januszewicz H, et al. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma 2007; 48: 596–600
   PubMed Web of Science ®Google Scholar
• Chen W, Parsons M, Torigian D A, Zhuang H, Alavi A. Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. Nucl Med Commun 2009; 30: 240–244
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiu Y, Zhuang H, Dadparvar S, Yu J Q, Dhurairaj T, Alavi A. Follow-up FDG PET in the evaluation of unexplained focal activity in the abdomen. Clin Nucl Med 2008; 33: 19–22
   PubMed Web of Science ®Google Scholar
• Tsamita C S, Golemi A, Egesta L, Castellucci P, Nanni C, Stefoni V, et al. Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. Nucl Med Commun 2008; 29: 705–710
   PubMed Web of Science ®Google Scholar
• Karam M, Roberts-Klein S, Shet N, Chang J, Feustel P. Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology. J Nucl Med 2008; 49: 1429–1436
   PubMed Web of Science ®Google Scholar
• Cohen P R, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol 2007; 25: 326–333
   PubMed Web of Science ®Google Scholar
• de Hemricourt E, De Boeck K, Hilte F, Abib A, Kockx M, Vandevivere J, De Bock R. Sarcoidosis and sarcoid-like reaction following Hodgkin's disease. Report of two cases. Mol Imaging Biol 2003; 5: 15–19
   PubMedGoogle Scholar
• Aide N, Allouache D, Ollivier Y, Switsers O, Bardet S. Early metabolic response 2′-deoxy-2′-(F18)fluoro-d-glucose PET metabolic response after corticosteroid treatment to differentiate cancer from sarcoidosis and sarcoidosis-like lesions. Mol Imaging Biol March, 2009, [Epub ahead of print]
   Google Scholar